Therapeutic Considerations in Metastatic HER2+ Breast Cancer | OncLive

Therapeutic Considerations in Metastatic HER2+ Breast Cancer

September 2, 2020

In this Onclive® webinar, leading experts will highlight how the field in HER2+ breast cancer is evolving and hear direct from leading experts. Join us Tuesday, September 15, 2020 at 8 PM EST.

Considerations in Metastatic HER2+ Breast Cancer

Tuesday, September 15, 2020

8:00-9:30 PM EDT

What are the latest options? How are advances today impacting the decisions a physician must make tomorrow?

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Willaim J. Gradishar, MD, FASCO, FACP and Adam Brufsky, MD, PhD.

Objectives:

  • Review and evaluate data on recent therapeutic advances in metastatic HER2+ breast cancer
  • Discuss clinical challenges and areas of uncertainty faced when selecting later lines of therapy for patients with metastatic HER2+ breast cancer
  • Identify factors that influence treatment selection and planning for patients with metastatic HER2+ breast cancer

William J. Gradishar, MD, FASCO, FACP

Betsy Bramsen Professor of Breast Oncology & Professor of Medicine
Chief, Division of Hematology/Oncology
Director, Maggie Daley Center for Women's Cancer Care
Deputy Director, Clinical Network
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Adam Brufsky, MD, PhD

Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Director, Comprehensive Breast Cancer Center
University of Pittsburgh School of Medicine
Pittsburgh, PA


x